IBIO, INC. Increase Decrease In Operating Lease Liability
IBIO, INC. (IBIO) reported Increase Decrease In Operating Lease Liability of -$490.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-28
- IBIO, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$127.00K.
- IBIO, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$124.00K.
- IBIO, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$122.00K.
- IBIO, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$117.00K.
- IBIO, INC. increase decrease in operating lease liability for fiscal 2026 was -$490.00K.
- IBIO, INC. increase decrease in operating lease liability for fiscal 2025 was -$436.00K.
- IBIO, INC. increase decrease in operating lease liability for fiscal 2024 was -$389.00K.
- IBIO, INC. increase decrease in operating lease liability for fiscal 2023 was -$101.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-28 | -$251.00K derived: sum of 2 quarters · filed 2026-08-28 | -$373.00K derived: sum of 3 quarters · filed 2026-08-28 | -$490.00K 10-K · filed 2026-08-28 |
| 2026-03-31 | -$124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | -$246.00K derived: sum of 2 quarters · filed 2026-05-12 | -$363.00K 10-Q · filed 2026-05-12 | -$476.00K derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | -$122.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-02-10 | -$239.00K 10-Q · filed 2026-02-10 | -$352.00K derived: sum of 3 quarters · filed 2026-08-28 | -$462.00K derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-09-30 | -$117.00K 10-Q/A · filed 2025-11-17 | -$230.00K derived: sum of 2 quarters · filed 2026-08-28 | -$340.00K derived: sum of 3 quarters · filed 2026-08-28 | -$449.00K derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | -$113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-28 | -$223.00K derived: sum of 2 quarters · filed 2026-08-28 | -$332.00K derived: sum of 3 quarters · filed 2026-08-28 | -$436.00K 10-K · filed 2026-08-28 |
| 2025-03-31 | -$110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | -$219.00K derived: sum of 2 quarters · filed 2026-05-12 | -$323.00K 10-Q · filed 2026-05-12 | -$416.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$109.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-02-10 | -$213.00K 10-Q · filed 2026-02-10 | -$306.00K derived: sum of 3 quarters · filed 2026-02-10 | -$407.00K derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-09-30 | -$104.00K 10-Q/A · filed 2025-11-17 | -$197.00K derived: sum of 2 quarters · filed 2025-11-17 | -$298.00K derived: sum of 3 quarters · filed 2025-11-17 | -$398.00K derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-05 | -$194.00K derived: sum of 2 quarters · filed 2025-09-05 | -$294.00K derived: sum of 3 quarters · filed 2025-09-05 | -$389.00K 10-K · filed 2025-09-05 |
| 2024-03-31 | -$101.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-02 | -$201.00K derived: sum of 2 quarters · filed 2025-05-02 | -$296.00K 10-Q · filed 2025-05-02 | -$388.00K derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-10 | -$195.00K 10-Q · filed 2025-02-10 | -$287.00K derived: sum of 3 quarters · filed 2025-02-10 | -$326.00K derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-09-30 | -$95.00K 10-Q · filed 2024-11-12 | -$187.00K derived: sum of 2 quarters · filed 2024-11-12 | -$226.00K derived: sum of 3 quarters · filed 2024-11-12 | -$193.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$92.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-24 | -$131.00K derived: sum of 2 quarters · filed 2024-09-24 | -$98.00K derived: sum of 3 quarters · filed 2024-09-24 | -$101.00K 10-K/A · filed 2024-09-24 |
| 2023-03-31 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-13 | -$6.00K derived: sum of 2 quarters · filed 2024-05-13 | -$9.00K 10-Q · filed 2024-05-13 | -$12.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-09 | $30.00K 10-Q · filed 2024-02-09 | $27.00K derived: sum of 3 quarters · filed 2024-02-09 | $26.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-09-30 | -$3.00K 10-Q · filed 2023-11-14 | -$6.00K derived: sum of 2 quarters · filed 2023-11-14 | -$7.00K derived: sum of 3 quarters · filed 2023-11-14 | -$18.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | -$4.00K derived: sum of 2 quarters · filed 2023-09-27 | -$15.00K derived: sum of 3 quarters · filed 2023-09-27 | -$15.00K 10-K · filed 2023-09-27 |
| 2022-03-31 | -$1.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-05-15 | -$12.00K derived: sum of 2 quarters · filed 2023-05-19 | -$12.00K 10-Q · filed 2023-05-15 | |
| 2021-12-31 | -$11.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-05-19 | -$11.00K 10-Q/A · filed 2023-05-19 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |